Total Funding
73
54
Total FundingSeries B raised
Growth Score
-5 pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
22936
XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.
- Ronald G. Crystal: MD and Founder
About the Company
XyloCor Therapeutics is a biotechnology company focused on creating gene therapies for patients with advanced coronary artery disease. Its lead product candidate, XC001, is in clinical development for patients with refractory angina, addressing significant unmet medical needs. The company aims to improve patient outcomes through innovative gene
therapy technologies developed in collaboration with Weill Cornell Medical College.
